[1] WHO. Weekly epidemiological update on COVID-19 - 9 November2021[EB/OL]. [2021-11-30]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. [2] KUMAR V, PARATE S, YOON S, et al.Computational simulations identified marine-derived natural bioactive compounds as replication inhibitors of SARS-CoV-2[J]. Front Microbiol, 2021(12): 647295. [3] SHANNON A, SELISKO B, LE N, et al.Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase[J]. BioRxiv, 2020(5): 098731. [4] WU F, ZHAO S, YU B, et al.A new coronavirus associated with human respiratory disease in China[J]. Nature, 2020, 579(7798): 265-269. [5] ZHOU P, YANG XL, WANG XG, et al.A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 579: 270-273. [6] PILLAIYAR T, MANICKAM M, NAMASIVAYAM V, et al.An overview of severe acute respiratory syndrome-coronavirus(SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy[J]. J Med Chem, 2016, 59(14): 6595-6628. [7] JIN Z, DU X, XU Y, et al.Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors[J]. 2020, 582(7811): 289-293. [8] MA C, SACCO MD, XIA Z, et al.Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a flipGFP-Based reporter assay[J]. ACS Cent Sci, 2021, 7(7): 1245-1260. [9] MOUFFOUK C, MOUFFOUK S, MOUFFOUK S, et al.Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CLpro and PLpro), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2)[J]. Eur J Pharmacol, 2021, 891: 173759. [10] MAHASE E.COVID-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports[J]. BMJ, 2021, 375: 2713. [11] DEVRIES M, MOHAMED AS, PRESCOTT RA, et al.A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL proinhibitor PF-00835231 as a potential new treatment for COVID-19[J]. J Virol, 2021, 95(10): e01819-01820. [12] BARILLI A, VISIGALLI R, FERRARI F, et al.Organic cation transporters (OCTs) in EpiAirway™,a cellular model of normal human bronchial epithelium[J]. Biomedicines, 2020, 8(5): 127. [13] OWEN DR, ALLERTON CMN, ANDERSON AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19[J]. Science, 2021(10): eabl4784. [14] BANKER MJ, CLARK TH, WILLIAMS JA.Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding[J]. J Pharm Sci, 2003, 92(5): 967-974. [15] National Institutes of Health (US). Coronavirus disease2019 (COVID-19) treatment guidelines[EB/OL].(2021-11-16)[2021-11-30]. https://www.ncbi.nlm.nih.gov/books/NBK570371/. [16] KLEMM T, EBERT G, CALLEJA DJ, et al.Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2[J]. EMBO J, 2020, 39(18): e106275. [17] RUT W, LV Z, ZMUDZINSKI M, et al. Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design[J]. Sci Adv, 2020, 6(42): eabd4596. [18] HERNANDEZ-SANTIAGO BI, BELTRAN T, STUYVER L, et al.Metabolism of the anti-hepatitis C virus nucleoside beta-D-N4-hydroxycytidine in different liver cells[J]. Antimicrob Agents Chemother, 2004, 48(12): 4636-4642. [19] PAINTER GR, BOWEN RA, BLUEMLING GR, et al.The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal Venezuelan equine encephalitis virus infection[J]. Antiviral Res, 2019, 171: 104597. [20] AGOSTINI ML, PRUIJSSERS AJ, CHAPPELL JD, et al.Small-molecule antiviral β-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance[J]. Virol, 2019, 93(24): e01348-19. [21] FERRON F, SUBISSI L, SILVEIRA DE MAT, et al.Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA[J]. Proc Natl Acad Sci USA, 2018, 115(2): E162-E171. [22] SMITH EC, BLANC H, SURDEL MC, et al.Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics[J]. PLoS Pathog, 2014, 10(7): e1004342. [23] GORDON CJ, TCHESNOKOV EP, SCHINAZI RF, et al.Molnup-iravir promotes SARS-CoV-2 mutagenesis via the RNA template[J]. J Biol Chem, 2021, 297(1): 100770. [24] KABINGER F, STILLER C, SCHMITZOVÁ J, et al.Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis[J] Nat Struct Mol Biol, 2021, 28(9): 740-746. [25] MERCK. Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study[EB/OL].(2021-10-01)[2021-11-30]. https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/. [26] PAINTER WP, HOLMAN W, BUSH JA, et al.Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2[J]. Antimicrob Agents Chemother, 2021, 65(5): e02428-20. [27] KHOO SH, FITZGERALD R, FLETCHER T, et al.Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study[J]. J Antimicrob Chemother, 2021, 76(12): 3286-3295. [28] FISCHER W, ERON JJ, HOLMAN W, et al.Molnupiravir, an oral antiviral treatment for COVID-19[J]. MedRxiv, 2021(6): 21258639. [29] ZHOU S, HILL CS, SARKAR S, et al.β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells[J]. J Infect Dis, 2021, 224(3): 415-419. [30] Veklury (remdesivir). USprescribing information[EB/OL].(2020-10-22)[2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf. [31] SHEAHAN TP, SIMS AC, GRAHAM RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses[J]. Sci Transl Med, 2017(9): eaal3653. [32] LO MK, JORDAN R, ARVEY A, et al.GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses[J]. Sci Rep, 2017(7): 43395. [33] WARREN TK, JORDAN R, LO MK, et al.Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys[J]. Nature, 2016, 531: 381-385. [34] GORDON CJ, TCHESNOKOV EP, WOOLNER E, et al.Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency[J]. J Biol Chem, 2020, 295: 6785-6797. [35] BEIGEL JH, TOMASHEK KM, DODD LE, et al.ACTT-1 Study Group Members. Remdesivir for the treatment of COVID-19 - final report[J]. N Engl J Med, 2020, 383(19): 1813-1826. [36] HUMENIUK R, MATHIAS A, KIRBY BJ, et al.pharmacokinetic, pharmacodynamic, and drug-interaction profile of remdesivir, a SARS-CoV-2 replication inhibitor[J]. Clin Pharmacokinet, 2021, 60(5): 569-583. [37] PAN H, PETO R, HENAO-RESTREPO AM, et al.WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19-interim WHO solidarity trial results[J]. N Engl J Med, 2020, 384: 497-511. [38] WANG Y, ZHANG D, DU G, et al.Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial[J]. Lancet, 2020, 395: 1569-1578. [39] SIMONIS A, THEOBALD SJ, FÄTKENHEUER G, et al. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2[J]. EMBO Mol Med, 2021, 13(1): e13105. [40] FDA. FDA approves first treatment for COVID-19[EB/OL].(2020-12-07)[2021-11-30]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19. 7 Dec 2020. [41] LAMB YN.Remdesivir: first approval[J]. Drugs, 2020, 80(13): 1355-1363. [42] SHIRAKI K, DAIKOKU T.Favipiravir, an anti-influenza drug against life threatening RNA virus infections[J]. Pharmacol Ther, 2020, 22: 107512. [43] MANLI W.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro[J]. Cell Research, 2020, 30: 269-271. [44] WANG Y, FAN G, SALAM A, et al.Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection[J]. J Infect Dis, 2020, 221: 1688-1698. [45] DU YX, CHEN XP.Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection[J]. Clin Pharmacol Ther, 2020, 108: 242-247. [46] JOSHI S, PARKAR J, ANSARI A, et al.Role of favipiravir in the treatment of COVID-19[J]. Int J Infect Dis, 2021, 102: 501-508. [47] CAI Q, YANG M, LIU D, et al.Experimental treatment with favipiravir for COVID-19:an open-label control study[J]. Engineering(Beijing), 2020, 6(10): 1192-1198. [48] YAMADA K.Anti-inflfluenza drug avigan tablet meets primary endpoint in phase iii clinical trial in Japan for COVID-19 patients[EB/OL]. [2021-11-30].https://asia.nikkei.com/Spotlight/Coronavirus/Japanese-approval-sought-for-Avigan-to-treatCOVID-19. |